公开(公告)号：US20220280495A1

公开(公告)日：2022-09-08

申请号：US17470136

申请日：2021-09-09

Applicant: AMGEN INC.

Inventor： Sean Caenepeel ,  Jude Canon ,  Paul Hughes ,  Jonathan D. Oliner ,  Richard J. Rickles ,  Anne Y. Saiki

IPC: A61K31/45 ,  A61K31/7068 ,  A61P35/02 ,  A61K9/00 ,  A61K31/704

Abstract: The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.

公开(公告)号：US20190290630A1

公开(公告)日：2019-09-26

申请号：US16229150

申请日：2018-12-21

Applicant: AMGEN INC.

Inventor： Sean Caenepeel ,  Jude Canon ,  Paul Hughes ,  Jonathan D. Oliner ,  Richard J. Rickles ,  Anne Y. Saiki

IPC: A61K31/451 ,  A61K31/365 ,  A61K31/635 ,  A61K31/704 ,  A61K31/706 ,  A61K31/166 ,  A61K31/7068 ,  A61K31/437 ,  A61K31/44 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/506 ,  A61K31/4045

Abstract: The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.

公开(公告)号：US12280056B2

公开(公告)日：2025-04-22

申请号：US18545932

申请日：2023-12-19

Applicant: Amgen Inc.

Inventor： James Russell Lipford ,  Jude Robert Canon ,  Anne Y. Saiki ,  Karen Louise Rex

IPC: A61P35/00 ,  A61K31/506 ,  A61K31/519 ,  A61K31/555 ,  C07K16/28

Abstract: The present invention provides combination therapy that includes an KRASG12C inhibitor, such as or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.

公开(公告)号：US11439645B2

公开(公告)日：2022-09-13

申请号：US16687563

申请日：2019-11-18

Applicant: Amgen Inc.

Inventor： James Russell Lipford ,  Jude Robert Canon ,  Anne Y. Saiki ,  Karen Louise Rex

IPC: A61P35/00 ,  A61K45/06 ,  A61K31/519 ,  A61K31/506 ,  A61K31/555 ,  C07K16/28

Abstract: The present invention provides combination therapy that includes an KRASG12C inhibitor, such as or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.

公开(公告)号：US11918584B2

公开(公告)日：2024-03-05

申请号：US17870573

申请日：2022-07-21

Applicant: Amgen Inc.

Inventor： James Russell Lipford ,  Jude Robert Canon ,  Anne Y. Saiki ,  Karen Louise Rex

IPC: A61K31/519 ,  A61K31/498 ,  A61K31/506 ,  A61K31/555 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K31/519 ,  A61P35/00 ,  A61K31/555 ,  C07K16/2818

Abstract: The present invention provides combination therapy that includes an KRASG12C inhibitor, such as




or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.

公开(公告)号：US10881648B2

公开(公告)日：2021-01-05

申请号：US16229150

申请日：2018-12-21

Applicant: AMGEN INC.

Inventor： Sean Caenepeel ,  Jude Canon ,  Paul Hughes ,  Jonathan D. Oliner ,  Richard J. Rickles ,  Anne Y. Saiki

IPC: A61K31/451 ,  A61K31/166 ,  A61K31/365 ,  A61K31/4045 ,  A61K31/437 ,  A61K31/44 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61K31/635 ,  A61K31/704 ,  A61K31/706 ,  A61K31/7068 ,  A61P35/02 ,  A61P35/00

Abstract: The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.